A phototherapy treatment apparatus and methods are provided. In particular, the present disclosure provides a phototherapy treatment apparatus configured to diffusely transmit light emitted from a light source to a patient.

Systems and methods to determine an indication of patient compliance and to determine an indication of patient condition are disclosed, including receiving physical activity information from a motion sensor, receiving a prescribed treatment including an activity threshold, determining an indication of patient compliance using a comparison of the received physical activity information occurring over a first period to the prescribed treatment, and determining an indication of patient condition using the received physical activity information occurring over a second period or with respect to a previously determined indication of patient condition.

Systems and methods to determine an indication of patient compliance or patient condition using received physical activity or temperature information are disclosed, including detecting physical activity of the patient, determining indications of patient compliance and patient condition using the detected physical activity, and providing the determined indications of patient compliance and patient condition to a user or process.

Systems and methods to determine an indication of patient compliance to a prescribed treatment are disclosed, including receive temperature information from a first temperature sensor in a housing of a self-contained monitoring device and from a second temperature sensor located outside of the housing of the self-contained monitoring device, receiving an indication of a prescribed treatment, and determining an indication of patient compliance to the prescribed treatment using the received temperature information occurring over a first period.

Systems and methods to determine an indication of patient compliance to a prescribed treatment are disclosed, including receive temperature information from a first temperature sensor in a housing of a self-contained monitoring device and from a second temperature sensor located outside of the housing of the self-contained monitoring device, receiving an indication of a prescribed treatment, and determining an indication of patient compliance to the prescribed treatment using the received temperature information occurring over a first period.

The present invention relates generally to therapeutic articles comprised of carbonaceous blend textile materials comprising yarns having about 25 to 100 weight % carbonaceous fiber and about 0 to 75 weight % fiber made of polyester, nylon, rayon, lyocell, cellulose, wool, silk, linen, bamboo, m-aramid, p-aramid, modacrylic, novoloid, melamine, regenerated cellulose, polyvinyl chloride, antistatic fiber, poly(p-phenylene benzobisoxazole) (PBO), polybenzimidazole (PBI), polysulphonamide (PSA), and combinations thereof, or other fibers not listed that are capable of being made into yarn and textile fabrics that are knit, woven, or nonwoven, and wherein the fabric has a weight from about 3 oz/yd.sup.2 to about 20 oz/yd.sup.2. Also encompassed within this invention is a method for using therapeutic textile articles having carbonaceous blend textile materials of the present disclosure for treatment of humans and animals with developmental neurological disorders, central nervous system disorders, autoimmune disorders, cardiovascular disease, sleep disorders, anxiety disorders, pain management, and diabetes.

The present invention relates generally to therapeutic articles comprised of carbonaceous blend textile materials comprising yarns having about 25 to 100 weight % carbonaceous fiber and about 0 to 75 weight % fiber made of polyester, nylon, rayon, lyocell, cellulose, wool, silk, linen, bamboo, m-aramid, p-aramid, modacrylic, novoloid, melamine, regenerated cellulose, polyvinyl chloride, antistatic fiber, poly(p-phenylene benzobisoxazole) (PBO), polybenzimidazole (PBI), polysulphonamide (PSA), and combinations thereof, or other fibers not listed that are capable of being made into yarn and textile fabrics that are knit, woven, or nonwoven, and wherein the fabric has a weight from about 3 oz/yd.sup.2 to about 20 oz/yd.sup.2. Also encompassed within this invention is a method for using therapeutic textile articles having carbonaceous blend textile materials of the present disclosure for treatment of humans and animals with developmental neurological disorders, central nervous system disorders, autoimmune disorders, cardiovascular disease, sleep disorders, anxiety disorders, pain management, and diabetes.

Embodiments include a heating blanket. The heating blanket may include a heating element and a shell covering the heating element. The heating element has elastic properties and is disposed in the shape of a sheet. The shell may have one or more sheets of polymeric material bonded together adjacent a perimeter of the heating element. One or more wires having malleable properties are secured within the shell. The wires allow the heating blanket to be secured to a patient.

Embodiments include a heating blanket. The heating blanket may include a heating element and a shell covering the heating element. The heating element has elastic properties and is disposed in the shape of a sheet. The shell may have one or more sheets of polymeric material bonded together adjacent a perimeter of the heating element. One or more wires having malleable properties are secured within the shell. The wires allow the heating blanket to be secured to a patient.

Described herein are components, systems, and methods of use of an integrated sterilization system comprising a pass-through logistics cabinet, an ozone sterilization system, a floor sterilization robot, and systems for controlling such components. An integrated operating room sterilization system will allow mitigation or elimination of risks (e.g., infrastructural risks (e.g., OI risks), procedural risks (e.g., risk of infection and contamination) that are associated with a setting in a healthcare environment. The elimination of clutter, control of major components under a unified and intuitive user interface, and the logical elimination of potential accumulated risk events (e.g., OI risks) and procedural risks are deliberately addressed, in whole or in part, by the present disclosure. The present disclosure describes the following: a pass-through logistics cabinet, an ozone sterilization system, a floor sterilization robot, and systems for controlling such components.